Cargando…
Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework
The Validation of HPV Genotyping Tests (VALGENT) framework is an international cooperation designed to evaluate human papillomavirus (HPV) assays with genotyping capabilities. Here, we assessed the performance of the BD Onclarity assay using Danish SurePath cervical screening samples collected under...
Autores principales: | Bonde, Jesper Hansen, Pedersen, Helle, Quint, Wim, Xu, Lan, Arbyn, Marc, Ejegod, Ditte Møller |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989063/ https://www.ncbi.nlm.nih.gov/pubmed/31723012 http://dx.doi.org/10.1128/JCM.01518-19 |
Ejemplares similares
-
The BD Onclarity HPV Assay on Samples Collected in SurePath Medium Meets the International Guidelines for Human Papillomavirus Test Requirements for Cervical Screening
por: Ejegod, Ditte, et al.
Publicado: (2016) -
Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samples
por: Ejegod, Ditte Møller, et al.
Publicado: (2016) -
Clinical Validation of the Onclarity Assay After Assay Migration to the High-Throughput COR Instrument Using SurePath Screening Samples From the Danish Cervical Cancer Screening Program
por: Ejegod, Ditte Møller, et al.
Publicado: (2021) -
Prevalence of Human Papillomavirus in 5,072 Consecutive Cervical SurePath Samples Evaluated with the Roche Cobas HPV Real-Time PCR Assay
por: Preisler, Sarah, et al.
Publicado: (2013) -
Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening
por: Ejegod, Ditte Møller, et al.
Publicado: (2020)